Autologous Matrix-induced Chondrogenesis Market By Material Type (Hyaluronic Acid, Polyethylene glycol (PEG), Collagen, Polylactic-co-glycolic Acid, Others), By Application (Knee Cartilage Repair, Elbow Cartilage Repair, Hip Cartilage Repair, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)), and Geography.


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Autologous Matrix-induced Chondrogenesis Market size was valued at 97.43 million in 2021 and is expected to reach 173.57 million by 2028, at a CAGR of 8.6% during the forecast period 2022 to 2028. Autologous matrix-induced chondrogenesis is single step cartilage restoration process that helps to repair the articular cartilage damage. In this process, the micro fracture is combines with the bi-layer collagen I/III.  Membrane. AMIC is developed for the treatment of osteochondral and traumatic chondral lesions to establish the first line treatment. The AMIC slows down the cartilage degeneration to delay or avoid the partial or total joint replacement surgery.

Global Autologous Matrix Induced Chondrogenesis Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Autologous Matrix-induced Chondrogenesis Market

Increase in the geriatric population more prone for bone and joint disorders is a key factor drives the global autologous matrix-induced chondrogenesis market. Moreover, rise in number of sports injuries, increase in the preference for minimally invasive surgical procedures, less post-operative complications and lower cost compared with conventional surgeries, increasing in the R&D for the advancement in AMIC, rise in disposable income, and increase in the awareness about AMIC in developed and emerging countries are anticipated to surge the global autologous matrix-induced chondrogenesis market over the forecast years. However, lack of favorable reimbursement policies and dearth of skilled professionals and clinical date are restrain the growth of autologous matrix-induced chondrogenesis market over the forecast timeframe.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Autologous Matrix Induced Chondrogenesis Market Segmentation

Material Type
  • Hyaluronic Acid
  • Polyethylene glycol (PEG)
  • Collagen
  • Polylactic-co-glycolic Acid
  • Others
  • Knee Cartilage Repair
  • Elbow Cartilage Repair
  • Hip Cartilage Repair
  • Others
By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


  • Anika Therapeutics, Inc. (U.S.)
  • Arthro-Kinetics AG (Germany)
  • Braun Melsungen AG (Germany)
  • BioTissue AG (Switzerland)
  • CartiHeal (Israel)
  • Geistlich Pharma AG (Switzerland)
  • JRI Orthopaedics Ltd. (AK Medical) (U.K.)
  • Matricel GmbH Germany)
  • Smith & Nephew plc (U.K.)
  • Zimmer Biomet Holdings (U.S.)